Sativex

Sativex® is GW's lead cannabinoid pharmaceutical product that is being developed for the treatment of spasticity due to multiple sclerosis, cancer pain and neuropathic pain of various origins

Medical Professionals

This section provides prescriber information, publications and clinical trials information.

Patients

Please note that we cannot provide advice on the suitability of Sativex for individual patients. Patients wishing to know more about Sativex should discuss with their doctor the most suitable treatment for them.

Multiple Sclerosis
Cancer Pain
Neuropathic Pain
Other

Information for physicians on the availability of Sativex in different countries.

Information for potential participants in ongoing trials and summary of completed trials.

Details of peer-review publications from completed clinical trials of Sativex.

GW has partnered with companies to market Sativex in countries around the world.

Pharmacology of Sativex and how its principal active components act in the body.